These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11717992)

  • 21. A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
    Gargan PE; Ploplis VA; Scheu JD
    Thromb Haemost; 1988 Jun; 59(3):426-31. PubMed ID: 3142080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
    Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug preparations of immobilized enzymes with enhanced affinity for the site of action].
    Torchilin VP; Maksimenko AV; Tishchenko EG; Papisov MI; Smirnov VN
    Antibiot Med Biotekhnol; 1986 Feb; 31(2):122-7. PubMed ID: 2421639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombolytic agents].
    Furukawa K
    Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1166-9. PubMed ID: 6503980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
    Kim JS; Kang JK; Chang HC; Lee M; Kim GS; Lee DK; Kim ST; Kim M; Park S
    J Korean Med Sci; 1993 Apr; 8(2):117-20. PubMed ID: 8397927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunoimaging of arterial and venous thrombi in canine model using 99mTc labeled monoclonal antifibrin antibody.
    Ruan C; Wang Q; He G; Wu J
    Chin Med J (Engl); 1997 Jan; 110(1):69-72. PubMed ID: 9594328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombus detection using a Tc-99m labeled antifibrin monoclonal antibody (MoAb). Experiments in vitro and in animals.
    Wasser MN; Pauwels EK; Nieuwenhuizen W
    Thromb Res Suppl; 1990; 10():91-104. PubMed ID: 2180115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
    Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Establishment of hybridoma secreting anti-mycobacteria monoclonal antibody by using electrofusion technique].
    Guo M; Pan Z; Wang H
    Wei Sheng Wu Xue Bao; 1998 Oct; 38(5):393-5. PubMed ID: 12549406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
    Nielsen LS; Andreasen PA; Grøndahl-Hansen J; Huang JY; Kristensen P; Danø K
    Thromb Haemost; 1986 Apr; 55(2):206-12. PubMed ID: 3520936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies monospecific to single-chain urokinase-type plasminogen activator (scu-PA).
    Scheuerlein JG; Kalies I; Gluth WP; Kalden JR
    Hybridoma; 1991 Jun; 10(3):395-9. PubMed ID: 1916850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lung endothelium targeting for pulmonary embolism thrombolysis.
    Ding BS; Zhou YJ; Chen XY; Zhang J; Zhang PX; Sun ZY; Tan XY; Liu JN
    Circulation; 2003 Dec; 108(23):2892-8. PubMed ID: 14610017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J; Binder BR; Huber K; Hoover RL
    Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Establishment of hybridomas secreting monoclonal antibodies to HIV-gp41 and HCV-NS3].
    Zhang S; Pi G; Gu S
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun; 13(2):128-9. PubMed ID: 12569777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies of predetermined specificity for fibrin: a rational approach to monoclonal antibody production.
    Hui KY; Haber E; Matsueda GR
    Hybridoma; 1986; 5(3):215-22. PubMed ID: 2429911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.